Soluble CD30 and CD26/DPPIV enzyme activity levels predict treatment outcome with interferon-alpha monotherapy and interferon-alpha/ribavirin combination therapy in chronic Hepatitis C virus (HCV) infection

Silvia Lee, G.C. Macquillan, N.M. Keane, G.P. Jeffrey, Patricia Price

    Research output: Chapter in Book/Conference paperOther chapter contribution

    Original languageEnglish
    Title of host publicationThe Twelfth Annual Combined Biological Sciences Meeting, Perth 2001
    EditorsB. Knight
    Place of PublicationPerth, WA
    Publication statusPublished - 2001

    Cite this

    Lee, S., Macquillan, G. C., Keane, N. M., Jeffrey, G. P., & Price, P. (2001). Soluble CD30 and CD26/DPPIV enzyme activity levels predict treatment outcome with interferon-alpha monotherapy and interferon-alpha/ribavirin combination therapy in chronic Hepatitis C virus (HCV) infection. In B. Knight (Ed.), The Twelfth Annual Combined Biological Sciences Meeting, Perth 2001 Perth, WA.
    Lee, Silvia ; Macquillan, G.C. ; Keane, N.M. ; Jeffrey, G.P. ; Price, Patricia. / Soluble CD30 and CD26/DPPIV enzyme activity levels predict treatment outcome with interferon-alpha monotherapy and interferon-alpha/ribavirin combination therapy in chronic Hepatitis C virus (HCV) infection. The Twelfth Annual Combined Biological Sciences Meeting, Perth 2001. editor / B. Knight. Perth, WA, 2001.
    @inbook{c2fe8c0c2fd84029ad168e75f6eb0920,
    title = "Soluble CD30 and CD26/DPPIV enzyme activity levels predict treatment outcome with interferon-alpha monotherapy and interferon-alpha/ribavirin combination therapy in chronic Hepatitis C virus (HCV) infection",
    author = "Silvia Lee and G.C. Macquillan and N.M. Keane and G.P. Jeffrey and Patricia Price",
    year = "2001",
    language = "English",
    editor = "B. Knight",
    booktitle = "The Twelfth Annual Combined Biological Sciences Meeting, Perth 2001",

    }

    Lee, S, Macquillan, GC, Keane, NM, Jeffrey, GP & Price, P 2001, Soluble CD30 and CD26/DPPIV enzyme activity levels predict treatment outcome with interferon-alpha monotherapy and interferon-alpha/ribavirin combination therapy in chronic Hepatitis C virus (HCV) infection. in B Knight (ed.), The Twelfth Annual Combined Biological Sciences Meeting, Perth 2001. Perth, WA.

    Soluble CD30 and CD26/DPPIV enzyme activity levels predict treatment outcome with interferon-alpha monotherapy and interferon-alpha/ribavirin combination therapy in chronic Hepatitis C virus (HCV) infection. / Lee, Silvia; Macquillan, G.C.; Keane, N.M.; Jeffrey, G.P.; Price, Patricia.

    The Twelfth Annual Combined Biological Sciences Meeting, Perth 2001. ed. / B. Knight. Perth, WA, 2001.

    Research output: Chapter in Book/Conference paperOther chapter contribution

    TY - CHAP

    T1 - Soluble CD30 and CD26/DPPIV enzyme activity levels predict treatment outcome with interferon-alpha monotherapy and interferon-alpha/ribavirin combination therapy in chronic Hepatitis C virus (HCV) infection

    AU - Lee, Silvia

    AU - Macquillan, G.C.

    AU - Keane, N.M.

    AU - Jeffrey, G.P.

    AU - Price, Patricia

    PY - 2001

    Y1 - 2001

    M3 - Other chapter contribution

    BT - The Twelfth Annual Combined Biological Sciences Meeting, Perth 2001

    A2 - Knight, B.

    CY - Perth, WA

    ER -

    Lee S, Macquillan GC, Keane NM, Jeffrey GP, Price P. Soluble CD30 and CD26/DPPIV enzyme activity levels predict treatment outcome with interferon-alpha monotherapy and interferon-alpha/ribavirin combination therapy in chronic Hepatitis C virus (HCV) infection. In Knight B, editor, The Twelfth Annual Combined Biological Sciences Meeting, Perth 2001. Perth, WA. 2001